Claims
- 1. An isolated polypeptide comprising a segment having an amino acid sequence at least 65% identical to SEQ ID NO: 5.
- 2. The isolated polypeptide of claim 1 wherein the segment is at least 80% identical to SEQ ID NO: 5.
- 3. The isolated polypeptide of claim 1 wherein the segment is at least 95% identical to SEQ ID NO: 5.
- 4. The isolated polypeptide of claim 1 wherein the segment is the sequence of SEQ ID NO: 5.
- 5. An isolated polypeptide comprising a segment of SEQ ID NO: 5 and containing at least 10 amino acids.
- 6. The isolated polypeptide of claim 5 wherein the segment contains at least 12 amino acids.
- 7. The isolated polypeptide of claim 6 wherein the segment contains at least 14 amino acids.
- 8. The isolated polypeptide of claim 7 wherein the segment contains at least 15 amino acids.
- 9. A phosphodiesterase comprising a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.
- 10. An isolated polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.
- 11. The isolated polypeptide of claim 10 wherein said polypeptide is purified.
- 12. An isolated 15-mer containing a segment of at least 12 amino acid residues of SEQ ID NO:5.
- 13. The isolated 15-mer of claim 12 wherein the segment contains at least 14 amino acid residues of SEQ ID NO:5.
- 14. An isolated polynucleotide coding for a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.
- 15. The polynucleotide of claim 14 wherein the polynucleotide is a DNA.
- 16. The polynucleotide of claim 15 wherein the DNA is a cDNA.
- 17. The polynucleotide of claim 14 wherein the polynucleotide is RNA.
- 18. The complement of the polynucleotide of claim 15.
- 19. An antibody specific for a polypeptide only when said polypeptide contains the segment of claims 1, 2, 3, 4, 5, 6, 7, or 8.
- 20. The antibody of claim 19 wherein said antibody is a monoclonal antibody.
- 21. A method of making a recombinant vector comprising inserting the polynucleotide of claim 15 into a vector.
- 22. A recombinant vector comprising the polynucleotide of claim 15.
- 23. A recombinant cell containing the polynucleotide of claim 14.
- 24. A method for producing a polypeptide comprising expressing from the recombinant cell of claim 23 the polypeptide encoded by said polynucleotide.
- 25. A process for diagnosing a disease in an animal afflicted therewith, or diagnosing a susceptibility to a disease in an animal at risk thereof, wherein said disease is related to an over-expression of a phosphodiesterase of claim 9 comprising determining the level of said phosphodiesterase activity in a cell from said animal.
- 26. The process of claim 25 wherein said animal is a human.
- 27. The method of claim 25 wherein the cell is a neuron.
- 28. The method of claim 25 wherein said disease involves the loss of memory.
- 29. The method of claim 28 wherein said loss of memory is a loss of long term memory.
- 30. A process for diagnosing a disease in an animal afflicted therewith, or a susceptibility to a disease in an animal at risk thereof, comprising determining a mutation in the genome of a neuron from said animal and wherein the mutation occurs in a nucleotide sequence coding for the 15-mer of SEQ ID NO:5.
- 31. The process of claim 30 wherein said animal is a human.
- 32. The process of claim 30 wherein said disease involves a loss of memory.
- 33. The process of claim 32 wherein said loss of memory is a loss of long term memory.
- 34. A process for screening chemical agents for phosphodiesterase modulating activity comprising: contacting a cell expressing a polypeptide coded for by the polynucleotide of claim 10 with a chemical agent having potential phosphodiesterase inhibitory activity and measuring the level of total cyclic adenosine monophosphate (cAMP) in said cell following said exposure wherein an altered level of cAMP in said cell following said exposure is an indicator of such moderating activity.
- 35. The method of claim 34 wherein the modulating activity is inhibitory activity.
- 36. A transgenic animal comprising within its genome one or more copies of the polynucleotide of claim 15.
- 37. The transgenic animal of claim 36 wherein said animal overproduces the expression product of said polynucleotide relative to a non-transgenic animal.
- 38. The transgenic animal of claim 37 wherein said animal is a mouse.
- 39. A transgenic animal whose genome lacks a gene expressing a functional PDE4D6 isoform or functional analog thereof.
- 40. The transgenic animal of claim 39 wherein said animal is a mouse.
- 41. A transgenic non-human animal whose genome comprises one or more genes coding for the human isoform of PDE4D6 in place of the mammalian gene otherwise coding for said isoform.
- 42. The transgenic animal of claim 41 wherein said animal is a mouse.
Parent Case Info
[0001] This application claims priority of U.S. Provisional Application Serial No. 60/141,196, filed 25 Jun. 1999, the disclosure of which is hereby incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60141196 |
Jun 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09602735 |
Jun 2000 |
US |
Child |
10682722 |
Oct 2003 |
US |